Warhound has emerged into the public eye, revealing a massive funding round of $200 million, with a total market valuation of $1.2 billion. The new company is the brainchild of a collaboration between Ben Lamm, founder of Colossal Biosciences, and Palmer Luckey, founder of Anduril, backed by prominent investors such as Sequoia, 8VC, and In-Q-Tel, which is affiliated with the U.S. Central Intelligence Agency.
Warhound focuses on engineering and developing genetically modified working dogs for the U.S. military, law enforcement agencies, and emergency response teams to execute missions that pose dangers to humans or are difficult for machines, such as explosive detection and complex search operations.
Foundation Background and Current Challenges
The project was launched following discussions between the founders regarding the reality of working dogs in the military sector; currently, the U.S. Department of Defense relies on imports from Europe for more than 80% of these dogs, and it has been found that less than half of them are actually qualified for active service. Furthermore, current dog breeds suffer from genetic predispositions to diseases such as cancer, hip dysplasia, and muscular dystrophy, in addition to poor eyesight issues.
Colossal intends to use its advanced gene-editing and cell-cloning technologies to produce improved strains of breeds such as the Belgian Malinois and the German Shepherd, with the goal of enhancing health, increasing average lifespan, and improving physical capabilities such as speed, agility, and sense of smell, alongside utilizing Viagen—also owned by Colossal—for cloning operations.
The Role of Technology and Anduril Equipment
Alongside genetic modifications, Anduril will equip the new dogs with advanced software and equipment, including protective vests equipped with sensors and specialized goggles, to transmit live data to operators and enhance field situational awareness. The founders emphasized that this equipment remains external and is not implanted inside the animal, which raises the safety level of the dogs and the human team members accompanying them.
What changes practically?
- The company plans to start cloning and incubating the first batch of dogs soon, expecting them to be born early next year and begin field service within two years.
- The company intends to sell these dogs to the military, police forces, and first responder entities without determining final pricing yet.
- The company operates under the guidance of the American Humane Society to ensure the adoption of training programs and secure the rehoming of the dogs upon their retirement through specialized programs.